Trials / Completed
CompletedNCT00725686
Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)
A Phase I Open-Label, Dose Escalation Trial Of REDD14NP Delivered By A Single Intravitreal Injection To Patients With Choroidal Neovascularization (CNV) Secondary To Exudative Age-Related Macular Degeneration ("Wet AMD").
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Quark Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD
Detailed description
Dose escalation safety study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-04523655 | This is a dose-escalation study (50, 100, 200, 400, 670, 1000, 1500, 2250, 3000 microgram) given at baseline and then the subject is followed up for 24 months |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2010-11-01
- Completion
- 2010-11-01
- First posted
- 2008-07-30
- Last updated
- 2012-10-10
Locations
11 sites across 2 countries: United States, Israel
Source: ClinicalTrials.gov record NCT00725686. Inclusion in this directory is not an endorsement.